Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, will combine its three subsidiaries into one unique name and brand. To accompany the rebrand, Banook Group has introduced a new logo and launched a new website, www.banookgroup.com.

The group’s subsidiaries, CardiaBase in Nancy, France, a cardiac core laboratory; Banook Central Imaging in Nancy, France, a global service organization providing medical image management for clinical research; and Banook in Mystic, Conn., the U.S. operational base, now are gathered under the Banook Group name. The three entities remain wholly owned subsidiaries. 

Using a single name reinforces the group’s strategy in centralizing its activities, expanding its line of services and strengthening its global positioning.

Banook Group now is one of the few groups able to offer a complete range of services in cardiac safety, central imaging and endpoint adjudication. Banook Group’s mission is to help its clients conduct clinical trials of the highest quality in the least amount of time, to secure regulatory approval and ultimately bring new solutions to the market for the benefit of patients worldwide.

Since its establishment in 1999, the group has achieved tremendous growth, including a 20% increase in turnover last year and diversification in its business activities. This rebrand is an important milestone for the Banook Group as it will help with the implementation of its worldwide growth strategy.

“Banook Group highly values improving the life of millions of patients throughout the world,” said Dr. Pascal Voiriot, president of Banook Group. “Banook Group represents a simple and modern update to the visual identity of the company. It is indicative of our corporate culture and commitment to connecting science and people. We never forget that behind the numbers, metrics and data flows, there are patients.”

Between 2014 and 2018, the CRO market is expected to grow at a 7.9% annual rate and reach the $32 billion mark in 2018, according to an ISR report. The central and core laboratories market (including cardiac safety and imaging assessment) represents almost 10% of this market ($3 billion a year) and is vital to the successful development of new drugs.